Mymetics Corporation (OTCQB: MYMX). We develop next-generation of prophylactic vaccines for infectious and life disabling diseases based on virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins and specifically designed antigens.

Cooperation possibilities

Collaboration possible in cancer immunotherapy either in combination with check point blockade or enhancing the response rates of existing cancer antigens by using our safe, proven, GMP ready proprietary virosome based vaccine platform (known for specific CD8+ and CD4+ Tcell increase)

Location
Facts & figures
  • Type of organization
    Public company
  • Year of foundation
    2000
  • Number of employees in Switzerland
    1-9